The European Parliament overwhelmingly approved the Critical Medicines Act, mandating re-shoring of critical drug production and reforming procurement to prioritize EU manufacturing amid global supply risks.

Leading global pharmaceutical companies are significantly increasing investments in Chinese manufacturing plants and R&D centers, positioning China as a key biotechnology hub amid regulatory reforms and market growth.

The European Parliament has approved a strengthened Critical Medicines Act, mandating at least 50% EU production for APIs and final products to enhance medicine supply security and reduce external dependencies.

The European Medicines Agency has issued a new scientific guideline and draft concept paper on non-clinical development and evaluation of microbiome-based medicinal products, impacting biotech and regulatory compliance in Europe.

South Korea's NHIS has approved reimbursement for XPOVIO in combination with bortezomib and dexamethasone for multiple myeloma patients after one prior therapy, effective March 1, 2026.

Bracco Imaging launches AI-powered contrast enhancement software AiMIFY® in the European Union and announces a new partnership with Avicenna.AI for AI applications in CT imaging at ECR 2026.

Cynosure Lutronic announces regulatory approvals for its Clarity II dual-wavelength laser system in China and Japan, expanding its footprint in Asia's regulated aesthetic medical device markets.

ACCURIDS launches AI-enabled EMA PMS Compliance Solution to automate data alignment and ensure readiness for XEVMPD decommissioning and EMA Strategy 2028 ahead of the Medicines for Europe conference on February 26-27, 2026.

Vietnam's government has approved a comprehensive national strategy to transform its pharmaceutical sector into a $20 billion industry by 2045, emphasizing manufacturing, regulatory upgrades, and foreign partnerships.[3]

Antengene Corporation and Shanghai Junshi Biosciences have entered a clinical collaboration to evaluate ATG-037 combined with JS207 for solid tumor treatment in Mainland China.